[Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation].

Abstract

AIM:

To assess efficacy of a potassium channel blocker nibentan for pharmacological cardioversion of persistent atrial fibrillation. Method. Nibentan (1% solution) was infused intravenously after 3 weeks of warfarin pretreatment to 31 patients with duration of atrial fibrillation from 4 weeks to 15 months.

RESULTS:

Sinus rhythm was restored in 24 patients. Mean dose of nibentan was 0.119+/-0.02 mg/kg. Proarrhythmic effects (paroxysmal or nonsustained polymorphic ventricular tachycardia) and substantial suppression of sinus rhythm automatism were registered in 3 and 3 patients, respectively.

CONCLUSION:

Nibentan is highly effective in persistent atrial fibrillation. It can be recommended for inhospital use in intensive care facilities.

• Authors: Iu V Shubik, M M Medvedev, A E Rivin
• Journal: Kardiologiia (Kardiologiia) Vol. 45 Issue 3 Pg. 19-23 ( 2005) ISSN: 0022-9040 [Print] Russia (Federation)
• PMID: 15821703 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Benzamides
• nibentan

Topics

• Adult
• Aged
• Aged, 80 and over
• Atrial Fibrillation (drug therapy, physiopathology)
• Benzamides (administration & dosage, therapeutic use)
• Electrocardiography
• Female
• Follow-Up Studies
• Heart Rate (drug effects)
• Humans
• Infusions, Intravenous
• Male
• Middle Aged
• Treatment Outcome